Announcements Trials
Browse Landscape

Phase

Phase 2 1

Status

Withdrawn 1

Sponsor Class

OTHER 1

Study Type

Interventional 1

Sponsor

Cancer Type

Other hematologic neoplasm 1Lymphoid 1

Conditions

Precursor Cell Lymphoblastic Leukemia-Lymphoma 18Leukemia 7Leukemia, Myeloid, Acute 6Recurrence 4Burkitt Lymphoma 4Lymphoma 3Leukemia, Biphenotypic, Acute 3Myelodysplastic Syndromes 2Precursor T-Cell Lymphoblastic Leukemia-Lymphoma 1Neoplasm, Residual 1Neoplasm Metastasis 1Lymphoma, B-Cell 1Leukemia, Prolymphocytic 1Hypersensitivity 1Hematologic Neoplasms 1

Interventions

fludarabine phosphate 37Cyclophosphamide 26Mycophenolic Acid 23Whole-Body Irradiation 22Peripheral Blood Stem Cell Transplantation 17Cyclosporine 16fludarabine 13Tacrolimus 13Antilymphocyte Serum 13Rituximab 10Cyclosporins 10Busulfan 10Filgrastim 8Sirolimus 7Methotrexate 7Therapeutics 5Granulocyte Colony-Stimulating Factor 5Cord Blood Stem Cell Transplantation 5ibrutinib 4Melphalan 4Cytarabine 4Allopurinol 4Thiotepa 3Epoetin Alfa 3Darbepoetin alfa 3Alemtuzumab 3thymoglobulin 2pegfilgrastim 2Stem Cell Transplantation 2Radiotherapy 2

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
OTHER × Leukemia, Prolymphocytic × asparaginase erwinia chrysanthemi recombinant × Clear all
NCT02718755 2018-06-26

Phase II Study of Fludarabine, Cytarabine (ARA-C) and Erwinase IV in Patients With Relapsed or Refractory Hematologic Malignancies

M.D. Anderson Cancer Center

Phase 2 Withdrawn
LymphoidOther hematologic neoplasm

Burkitt Lymphoma, Lymphoma, Recurrence, Leukemia, Biphenotypic, Acute, Leukemia, Prolymphocytic, Leukemia, Myeloid, Acute, Lymphoma, B-Cell, Hematologic Neoplasms, Precursor Cell Lymphoblastic Leukemia-Lymphoma

Data powered by HemOnc (CC BY 4.0) Colophon âš¡